Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMPH.L Regulatory News (MPH)

  • There is currently no data for MPH

AGM Statement

6 Sep 2007 07:00

Marchpole Holdings PLC06 September 2007 Marchpole Holdings plc ("Marchpole" or "the Company") Annual General Meeting Statement At Marchpole Holdings Annual General Meeting to be held this morning thenon-executive Chairman of Marchpole Holdings plc, Christopher Phillips, willgive the following statement and update on current trading. "At the time of the announcement on 28 June 2007 of our results for the yearended 31 March 2007 I was pleased to report continued significant improvement inthe business with increased turnover and profitability. The Group continues toevolve into a diversified international luxury brand management business with aglobally recognised portfolio of fashion brands. Our global reach is expandingand we now operate in the UK, Continental and Eastern Europe, Asia, the Americasand the Middle East. The current financial year has started in line with expectations with our Spring/Summer 2008 collections having been well received and forward order booksbuilding as anticipated. Sales of Emanuel Ungaro and Ungaro Homme in Europe,including the UK, are encouraging and in line with our expectations and demandfor the new Emanuel Ungaro first line, designed by Franck Boclet, has exceededour expectations. Our wholly owned brand Jean Charles de Castelbajac ("JCC")continues to enjoy both increased sales, and increased licensing income. On alike-for-like basis JCC sales have delivered an increase of 5%, and increasedlicensing income has derived from both new licences and royalty income which hasmore than doubled on existing licences. Good progress continues to be made with the Emanuel Ungaro and Ungaro Hommelicences where we continue to work very closely with the House of Ungaro. Arecent development is the signing of a five year royalty and licensing agreementfor Colombia which represents our first breakthrough into the South Americanmarket. This agreement will see the opening of an Emanuel Ungaro flagship storein Bogota and distribution through a further 28 specialist menswear outlets.Furthermore, two new flagship stores are to be opened in the near future inBucharest and Azerbaijan, extending the brand's reach. The development of our JCC brand is progressing in line with strategy. Twosignificant long term partnership agreements have recently been signed with theworld famous headwear company New Era and one of the world's original denimcompanies, Lee Cooper, Under the terms of the Lee Cooper agreement we willdistribute an exclusive 'JC-DC' denim collection to 250 Lee Cooper stores. TheJCC brand continues to strengthen its presence in the Far East. Most recently anew distribution agreement has been signed with Coronet, a member of the Itochugroup, for Japan and later this month we will be opening of a new JCC flagshipstore in Tokyo. . We continue to develop and sell the Boateng collection and sales and orders havegrown from last year, despite the dispute over licence arrangements with BespokeCouture. This was settled by the Court of Appeal in Marchpole's favour inDecember 2006 and our commitment to the brand remains unaltered. We are pleased to report that the integration of Greenmark Limited, the ladiesfootwear designer and importer, which was acquired in March 2007, has beensuccessful and we are seeing increased sales and improved margins. Homebody, the luxury clothing company which designs, manufactures anddistributes ladieswear, maternity wear and menswear which was acquired last yearhas been fully integrated into the Marchpole business model and continues tomake good progress and increase sales and distribution. A European multi-lingualwebsite went live this week and we are confident that this will deliver asignificant increase in internet sales. We therefore look forward to the future with confidence. The business continuesto perform in line with expectations with a pipeline of new opportunities fromwhich the Company is well placed to capitalise, and deliver returns toshareholders. For technical reasons Resolutions 7-11 will not be placed before today'smeeting. An explanatory letter is being sent to shareholders and theseresolutions will be put to shareholders at an EGM which will be held at theearliest possible date. For further information, please contact : Bell Pottinger Corporate & Financial 020 7861 3232Emma Kent / Amy Rajendran Marchpole Holdings plc 020 7908 7777Michael Morris, Executive Deputy Chairman Note to Editors: - Marchpole Holdings plc ("Marchpole") is an international brandmanagement group that designs, produces and sells clothing and accessories forten globally recognised fashion labels. It operates in all of the world's mainmarkets - UK, mainland Europe, Middle East, Asia and the USA - Its respected brands include Boateng, Emanuel Ungaro, Ungaro Homme,Jean Charles de Castelbajac ("JCC"), Jean Charles de Castelbajac / Rossignol,Jean Charles de Castelbajac/Okaidi, Jean Charles de Castelbajac / New Era, JCDC/Lee Cooper and Homebody and Homemummy - Marchpole is renowned for its integrated approach to brandmanagement, taking a brand from concept to design studio to the customerinterface. - The Group has grown considerably in the past four years, from alicensee with one core licence (YSL menswear) - to today's internationalbusiness that manages its brands across a multitude of clothing lines andaccessories - Marchpole's acquisition (March 2006) of Moda America - the USlicensee for leading designer Emanuel Ungaro - provided further growthopportunities in the UK and America and strengthened the Company's relationshipwith Ungaro - The acquisition also enabled the Company to launch the Ungaro brand,already established by Marchpole in Europe and Asia, into the US, Canada andSouth America. The acquisition has also enabled the Company to re-launch JCCinto America. - In March 2007 Marchpole acquired 100% of Greenmark Limited, an importer and wholesaler of ladies shoes who currently supply in excess of 2.5 million pairs of shoes per annum. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
28th Feb 202012:00 pmRNSPositive feedback from phase 2 meeting with FDA
25th Feb 20203:00 pmRNSHolding(s) in Company
21st Feb 20202:31 pmRNSHolding(s) in Company
21st Feb 20202:30 pmRNSHolding(s) in Company
20th Feb 20204:41 pmRNSSecond Price Monitoring Extn
20th Feb 20204:36 pmRNSPrice Monitoring Extension
20th Feb 20204:06 pmRNSDirector and other PDMR Dealings
19th Feb 20208:00 amRNSEquity Investment
18th Feb 202011:00 amRNSPrice Monitoring Extension
13th Feb 202010:45 amRNSHolding(s) in Company
12th Feb 20204:00 pmRNSHolding(s) in Company
12th Feb 20201:00 pmRNSUpdate on Distribution
11th Feb 20203:00 pmRNSHolding(s) in Company
10th Feb 20202:06 pmRNSSecond Price Monitoring Extn
10th Feb 20202:00 pmRNSPrice Monitoring Extension
10th Feb 202012:00 pmRNSNovartis Financing; Purchase Agreement with Aspire
28th Jan 20202:05 pmRNSSecond Price Monitoring Extn
28th Jan 20202:00 pmRNSPrice Monitoring Extension
14th Jan 202012:00 pmRNSAdditional positive data from phase 2b study
13th Jan 20204:41 pmRNSSecond Price Monitoring Extn
13th Jan 20204:35 pmRNSPrice Monitoring Extension
13th Jan 202012:00 pmRNSMereo and Oncologie Global Licensing Agreement
6th Jan 20204:45 pmRNSHolding(s) in Company
2nd Jan 202011:05 amRNSSecond Price Monitoring Extn
2nd Jan 202011:00 amRNSPrice Monitoring Extension
31st Dec 201911:00 amRNSPrice Monitoring Extension
27th Dec 201911:05 amRNSSecond Price Monitoring Extn
27th Dec 201911:00 amRNSPrice Monitoring Extension
18th Dec 20192:22 pmRNSNotification of Major Holdings in Company
16th Dec 20192:17 pmRNSNotification of Holdings in Company
3rd Dec 20194:54 pmRNSPDMR Shareholding
27th Nov 20194:12 pmRNSDirector Shareholding
25th Nov 20195:02 pmRNSDirector Shareholding
22nd Nov 20195:09 pmRNSDirector/PDMR Shareholding
20th Nov 20192:31 pmRNSPDMR Shareholding
11th Nov 201911:05 amRNSSecond Price Monitoring Extn
11th Nov 201911:00 amRNSPrice Monitoring Extension
11th Nov 20197:00 amRNSMereo BioPharma Phase 2b ASTEROID Study
18th Oct 20197:00 amRNSHoldings in Company
17th Oct 20192:20 pmRNSHoldings in Company
14th Oct 201912:21 pmRNSNotification of Director Dealing
7th Oct 20191:00 pmRNSFDA Fast Track Designation for Navicixizumab
4th Oct 20192:57 pmRNSPDMR Notification
2nd Oct 20193:54 pmRNSPDMR Notification
26th Sep 201912:04 pmRNSPDMR Dealing
25th Sep 201910:38 amRNSPDMR Dealing
24th Sep 20191:00 pmRNSDirector Dealing
20th Sep 20192:22 pmRNSDirector Shareholding
17th Sep 20197:00 amRNSInterim results for 6 months ended June 30, 2019
13th Sep 20193:30 pmRNSDirectors' details update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.